C3 and neoplasm: Regarding complement modulation in the setting of CNS neoplastic disease, major frontiers in complement-targeted therapeutics in glioma are likely to include a focus on C1q-targeted therapeutics, given its consistent role in driving tumor progression, as well as C3-targeted therapeutics in the context of radiation to limit radiation-induced edema and degeneration allowing for maximal treatment dosing.